The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Urothelial tumorigenesis: a tale of divergent pathways
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 2,020
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Reddy, E. P., Reynolds, R. K., Santos, E., & Barbacid, M. (1982) · Nature · doi:10.1038/300149a0 · Cited by 1,391
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
Gonzalez‐Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T. T., Beart, R. W., Tornout, J. M. V., & Jones, P. A. (1995) · PubMed · Cited by 772
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Two molecular pathways to transitional cell carcinoma of the bladder.
Spruck, C., Ohneseit, P. F., Gonzalez‐Zulueta, M., Esrig, D., Miyao, N., Tsai, Y., Lerner, S. P., Schmütte, C., Yang, A. S., & Cote, R. (1994) · PubMed · Cited by 680
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
Vihinen, P., & Kähäri, V. (2002) · International Journal of Cancer · doi:10.1002/ijc.10329 · Cited by 637
Hernando, E., Nahlé, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., Michel, L., Mittal, V., Gerald, W., Benezra, R., et al. (2004) · Nature · doi:10.1038/nature02820 · Cited by 562
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway
Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., Rogi, T., Tanaka, S., Suda, M., et al. (2004) · Nature Medicine · doi:10.1038/nm971 · Cited by 394
p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer
Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., & Lerner, S. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.118 · Cited by 327
Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Nichols, P. W., Taylor, C. R., Cote, R. J., Groshen, S., Dunn, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.3.219 · Cited by 319
Lifetime Risks of Common Cancers Among Retinoblastoma Survivors
Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh058 · Cited by 312
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder Cancer
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1072 · Cited by 299
Conditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc777 · Cited by 294
Dinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Self-citationTrudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Bakkar, A., Wallerand, H., Radvanyi, F., Lahaye, J.-B., Pissard, S., Lecerf, L., Kouyoumdjian, J. C., Abbou, C. C., Pairon, J. ‐., Jaurand, M., et al. (2003) · PubMed · Cited by 270
p53 and treatment of bladder cancer
Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997) · Nature · doi:10.1038/385123b0 · Cited by 269
Mdm2: keeping p53 under control
Piette, J., Neel, H., & Maréchal, V. (1997) · Oncogene · doi:10.1038/sj.onc.1201432 · Cited by 266
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Chatterjee, S. J., Datar, R., Youssefzadeh, D., George, B., Goebell, P. J., Stein, J. P., Young, L., Shi, S.-R., Gee, C., Groshen, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.174 · Cited by 254
Logothetis, C. J., Xu, H.-J., Ro, J. Y., Hu, S.-X., Sahin, A., Ordonez, N., & Benedict, W. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1256 · Cited by 244
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Genetic alterations in bladder cancer
Dalbagni, G., Presti, J., Fair, W. R., Reuter, V., & Cordon-Cardo, C. (1993) · The Lancet · doi:10.1016/0140-6736(93)91595-d · Cited by 238
van Rhijn, B. W. G., van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2421 · Cited by 227
Hartmann, A., Schlake, G., Zaak, D., Hungerhuber, E., Hofstetter, A. G., Hofstaedter, F., & Knuechel, R. (2002) · PubMed · Cited by 216
FGFs, their receptors, and human limb malformations: Clinical and molecular correlations
Wilkie, A. O. M., Patey, S. J., Kan, S., van den Ouweland, A. M. W., & Hamel, B. C. J. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10775 · Cited by 201
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Gonzalgo, M. L., Hayashida, T., Bender, C. M., Pao, M. M., Tsai, Y., Gonzales, F. A., Nguyen, H. D., Nguyen, T. T., & Jones, P. A. (1998) · PubMed · Cited by 200
Role of T antigen interactions with p53 in tumorigenesis
Pipas, J. M., & Levine, A. J. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0343 · Cited by 199
Sänchez‐Carbayo, M., Socci, N. D., Charytonowicz, E., Lu, M.-L., Prystowsky, M. B., Childs, G. J., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 197
Hartmann, A., Moser, K., Kriegmair, M., Hofstetter, A., Hofstaedter, F., & Knuechel, R. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65318-7 · Cited by 189
Frequent FGFR3 mutations in urothelial papilloma
van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C., & van der Kwast, T. H. (2002) · The Journal of Pathology · doi:10.1002/path.1202 · Cited by 189
Deletion of the p16 and p15 Genes in Human Bladder Tumors
Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V. E., Zhang, Z.-F., Beach, D., & Cordon-Cardo, C. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.20.1524 · Cited by 184
Cairns, P., Proctor, A. J., & Knowles, M. A. (1991) · PubMed · Cited by 168
Zhang, Z. T., Pak, J., Shapiro, E., Sun, T., & Wu, X. (1999) · PubMed · Cited by 168
Self-citationFeinberg, A. P., Vogelstein, B., Droller, M. J., Baylin, S. B., & Nelkin, B. D. (1983) · Science · doi:10.1126/science.6304875 · Cited by 163
Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., & Bergsagel, P. L. (2004) · Blood · doi:10.1182/blood-2003-10-3650 · Cited by 162
Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation
Zhang, Z.-T., Pak, J., Huang, H.-Y., Shapiro, E., Sun, T.-T., Pellicer, A., & Wu, X.-R. (2001) · Oncogene · doi:10.1038/sj.onc.1204315 · Cited by 159
Self-citationTherapeutic targeting in the estrogen receptor hormonal pathway
Katzenellenbogen, B. S., & Frasor, J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.004 · Cited by 159
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, E., Chase, A., Heath, C., Rahemtulla, A., & Cross, N. (2004) · Leukemia · doi:10.1038/sj.leu.2403347 · Cited by 158
Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer
Simon, R., Struckmann, K., Schraml, P., Wagner, U., Forster, T., Moch, H., Fijan, A., Bruderer, J., Wilber, K., Mihatsch, M. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205304 · Cited by 157
Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder Carcinomas
Kömhoff, M., Guan, Y., Shappell, H. W., Davis, L. S., Jack, G. S., Shyr, Y., Koch, M. O., Shappell, S. B., & Breyer, M. D. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64513-0 · Cited by 149
Brunner, T. B., Hahn, S. M., Gupta, A., Muschel, R. J., McKenna, W. G., & Bernhard, E. J. (2003) · PubMed · Cited by 147
(2002) · PubMed · Cited by 143
Ornan, E. M., Adar, R., Feferman, T., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.516-522.2000 · Cited by 140
Signal Transduction Pathway of Human Fibroblast Growth Factor Receptor 3
Kanai, M., Göke, M. N., Tsunekawa, S., & Podolsky, D. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6621 · Cited by 139
Kuball, J. H. E., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D. C., Grace, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.957 · Cited by 135
Knowles, M. A., & Williamson, M. P. (1993) · PubMed · Cited by 131
Hart, K. C., Robertson, S. C., & Donoghue, D. J. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.4.931 · Cited by 131
Obermann, E. C., Junker, K., Stoehr, R., Dietmaier, W., Zaak, D., Schubert, J., Hofstaedter, F., Knuechel, R., & Hartmann, A. (2002) · The Journal of Pathology · doi:10.1002/path.1259 · Cited by 129
Rauchenberger, R., Borges, E., Thomassen-Wolf, E., Rom, E., Adar, R., Yaniv, Y., Malka, M., Chumakov, I., Kotzer, S., Resnitzky, D., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303164200 · Cited by 127
Novel approaches with targeted therapies in bladder cancer
Joaquim Bellmunt, B., Hussain, M., & Dinney, C. P. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00067-2 · Cited by 125
Feng, Z. (2002) · Carcinogenesis · doi:10.1093/carcin/23.10.1721 · Cited by 120
Molecular alterations in bladder cancer
Orntoft, T. F., & Wolf, H. (1998) · Urological Research · doi:10.1007/s002400050050 · Cited by 119
Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia
Cho, J. Y., Guo, C., Torello, M., Lunstrum, G. P., Iwata, T., Deng, C., & Horton, W. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237184100 · Cited by 116
Knowles, M. A., Habuchi, T., Kennedy, W., & Cuthbert-Heavens, D. (2003) · PubMed · Cited by 111
Rieger‐Christ, K., Mourtzinos, A. P., Lee, P. J., Zagha, R. M., Cain, J. E., Silverman, M. L., Libertino, J. A., & Summerhayes, I. C. (2003) · Cancer · doi:10.1002/cncr.11536 · Cited by 109
Korkolopoulou, P. A., Christodoulou, P. N., Kapralos, P., Exarchakos, M., Bisbiroula, A., Hadjiyannakis, M., Georgountzos, C., & Thomas-Tsagli, E. (1997) · Pathology - Research and Practice · doi:10.1016/s0344-0338(97)80055-6 · Cited by 100
Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes
McNeish, I. A., Bell, S. J. D., & Lemoine, N. R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302238 · Cited by 100
Farnesyltransferase inhibitors
Sebti, S. M., & Adjei, A. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.012 · Cited by 100
Agazie, Y. M., Movilla, N., Ischenko, I., & Hayman, M. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206798 · Cited by 88
Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway
Rieger‐Christ, K., Lee, P., Zagha, R. M., Kosakowski, M., Moinzadeh, A., Stoffel, J. T., Ben‐Ze'ev, A., Libertino, J. A., & Summerhayes, I. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207629 · Cited by 88
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
Sibley, K., Stern, P., & Knowles, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204543 · Cited by 88
Paterson, J., Li, Z.-H., Wen, X., Masih-Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 87
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder
Shariat, S. F., Pahlavan, S., Baseman, A. G., Brown, R. M., Green, A. E., Wheeler, T. M., & Lerner, S. P. (2001) · Urology · doi:10.1016/s0090-4295(00)00892-x · Cited by 87
Luu, Y., Bush, J., Cheung, K. J., & Li, G. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5526 · Cited by 86
CpG hypermethylation of promoter region and inactivation of E‐cadherin gene in human bladder cancer
Ribeiro‐Filho, L. A., Franks, J., Sasaki, M., Shiina, H., Li, L.-C., Nojima, D., Arap, S., Carroll, P. R., Enokida, H., Nakagawa, M., et al. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10064 · Cited by 86
Memon, A. A., Sørensen, B. S., Meldgaard, P., Fokdal, L. U., Thykjær, T., & Nexø, E. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602251 · Cited by 86
Wallerand, H. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh275 · Cited by 86
Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder*1
WAGNER, U., Sauter, G., Moch, H., Novotná, H., Epper, R., Mihatsch, M. J., & Waldman, F. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90086-1 · Cited by 83
Popov, Z., de Medina, S. G. D., Lefrère-Belda, M.-A., Hoznek, A., Bastuji‐Garin, S., Abbou, C. C., Thiery, J. P., Radvanyi, F., & Chopin, D. K. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1233 · Cited by 82
Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy
Cordon‐Cardo, C., Côté, R. J., & Sauter, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169338 · Cited by 78
Lin, J., Zhao, H., & Sun, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.679 · Cited by 71
Slaton, J. W., Karashima, T., Perrotte, P., Inoue, K., Kim, S. J., Izawa, J. I., Kedar, D. J., McConkey, D. J., Millikan, R. E., Sweeney, P., et al. (2001) · PubMed · Cited by 63
Gao, J. X., Huang, H. Y., Pak, J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207169 · Cited by 59
Demma, M. J., Wong, S., Maxwell, E., & Dasmahapatra, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401854200 · Cited by 58
H-RAS, K-RAS, and N-RAS Gene Activation in Human Bladder Cancers
Przybojewska, B., Jagiełło, A., & Jałmużna, P. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00223-5 · Cited by 57
Hinata, N., Shirakawa, T., Zhang, Z., Matsumoto, A., Fujisawa, M., Okada, H., Kamidono, S., & Gotoh, A. (2003) · Urological Research · doi:10.1007/s00240-003-0355-9 · Cited by 46
Zhang, X., Multani, A. S., Zhou, J., Shay, J. W., McConkey, D. J., Dong, L., Kim, C.-S., Rosser, C. J., Pathak, S., & Benedict, W. F. (2003) · PubMed · Cited by 44
FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
Fracchiolla, N., Luminari, S., Baldini, L., Lombardi, L., Maiolo, A., & Neri, A. (1998) · Blood · doi:10.1182/blood.v92.8.2987 · Cited by 40
Wu, R., Connolly, D., Ngelangel, C., Bosch, F., Muñoz, N., & Cho, K. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203934 · Cited by 37
Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin
Kikuchi, E., Menéndez, S., Ohori, M., Cordon‐Cardo, C., Kasahara, N., & Bochner, B. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0099 · Cited by 36
Cited by
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 877
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., Wu, R., Chen, C., Li, X., Zhou, L., et al. (2011) · Nature Genetics · doi:10.1038/ng.907 · Cited by 747
Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H. Y., van de Rijn, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906549106 · Cited by 660
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., et al. (2015) · Nature · doi:10.1038/nature14034 · Cited by 578
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Metadata
- Authors
- Wu, X.-R.
- Venue
- Nature Reviews Cancer
- Published
- 2005-08-19
- Volume
- 5
- Issue
- 9
- Pages
- 713-725
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2018561776
- Cited by
- 692
- References
- 102
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.